scholarly journals Pathogenicity of Philippine and Indonesian Trypanosoma evansi Isolates in Mice and Their Responses to Trypanocides

2021 ◽  
Vol 26 (1) ◽  
pp. 22
Author(s):  
Alan P Dargantes ◽  
April Hari Wardhana ◽  
Jose Alexander C Abella ◽  
Milkesidick R Sequito ◽  
Simon A Reid ◽  
...  
Keyword(s):  
Control Strategy ◽  
Post Infection ◽  
The Philippines ◽  
Trypanosoma Evansi ◽  
Prepatent Period ◽  
Diminazene Aceturate ◽  
Sulphate Chloride

Pathogenicity of 10 isolates of <em>T. evansi</em> collected from  Mindanao, Philippines, and one isolate from East Java, Indonesia was determined and compared. The susceptibility of these isolates against diminazene aceturate, melarsomine dihydrochloride, suramin and quinapyramine sulphate/chloride was also tested. Twenty-five mice were infected intraperitoneally with each isolate and 20 were treated with the 4 drugs (5 mice/drug) while 5 infected and 7 uninfected mice served as infected-untreated and uninfected controls, respectively. Treatment was carried out 24 hours post-infection and parasitemia was monitored for 35 days. Mice infected with Philippine isolates significantly died earlier (5-11 days) than those infected with the Indonesian isolate (14-16 days). The prepatent period for Philippine isolates (3-8 days) was significantly shorter than the Indonesian strain (11-13 days).  Trypanosomes were not observed in the blood of mice infected with any of the Philippine isolates when treated with quinapyramine sulphate/chloride, melarsomine dihydrochloride or suramin. Two of 10 mice infected with either C4 or A9 Philippine isolates and treated with diminazene aceturate had parasitemia on days 29 and 31, respectively. It is concluded that isolates of <em>T. evansi</em> from Mindanao, Philippines, are more pathogenic than the isolate from East Java, Indonesia. This study also indicated that quinapyramine sulphate/chloride, melarsomine dihydrochloride and suramin are effective against these <em>T. evansi</em> isolates from Mindanao, Philippines and East Java, Indonesia, while two of the Mindanao isolates are resistant to diminazene. This information is valuable in the enhancement of the control strategy against surra in the Philippines and Indonesia.

Nerolidol nanospheres increases its trypanocidal efficacy against Trypanosoma evansi: New approach against diminazene aceturate resistance and toxicity

2016 ◽  
Vol 166 ◽  
pp. 144-149 ◽  
Author(s):  
Matheus D. Baldissera ◽  
Thirssa H. Grando ◽  
Carine F. Souza ◽  
Luciana F. Cossetin ◽  
Michele R. Sagrillo ◽  
...  
Keyword(s):  
Trypanosoma Evansi ◽  
Diminazene Aceturate ◽  
New Approach

scholarly journals Trypanocidal activity of methanol extracts of the hemolymph of Sarcophaga argyrostoma larva against Trypanosoma evansi infected mice

2020 ◽  
Vol 13 (8) ◽  
pp. 1599-1604
Author(s):  
Doaa S. Farghaly ◽  
Al-Shaimaa M. Sadek
Keyword(s):  
Blood Cells ◽  
Unit Volume ◽  
Methanol Extract ◽  
White Blood Cells ◽  
Negative Control ◽  
Trypanosoma Evansi ◽  
Diminazene Aceturate ◽  
Standard Drug ◽  
Trypanocidal Activity ◽  
Sarcophaga Argyrostoma

Background and Aim: Many natural products worldwide are used for medicinal purposes. Various insect-isolated compounds were investigated in pursuit of new therapeutic agents. This study aimed to compare the effects of methanol extract of hemolymph of Sarcophaga argyrostoma larvae with diminazene aceturate on some hematological and biochemical indices of mice infected with Trypanosoma evansi. Materials and Methods: Sixteen albino mice were randomly divided into four groups, of four mice, which received different treatments: In Group 1 (G1), mice were infected intraperitoneally with 1×104 T. evansi and received no treatment (positive control), in Group 2 (G2), infected mice were treated with 0.5 mL/kg of diminazene aceturate, in Group 3 (G3), infected mice were treated with 0.5 mL/kg methanol extract of the hemolymph of S. argyrostoma larvae, and in Group 4 (G4), uninfected mice received 0.5 ml of distilled water (negative control). In G3, treatment was started 3 days before injecting the parasite, while for the other groups, a single dose of treatment was applied when the parasite appeared in the blood. Results: Mice from G3 showed low parasitemia of 29×104/mm3 4 days post-infection until the infection completely disappeared on the 5th day, which was earlier than for other groups. The results showed that the numbers of red blood corpuscles (red blood cells [RBCs]) and white blood cells (WBCs) per unit volume were significantly different (p<0.05) between the four groups. The highest RBC (9.09×103 cell/ mm3) and WBC (14.30×103 cell/ mm3) counts were recorded in G3, whereas the lowest values of 6.60 and 4.60×103cell/ mm3, respectively, were recorded for G2. In addition, there were significant differences (p<0.05) between the different groups for platelet counts per unit volume, with G3 having the most (943×103 cell/ mm3) and G2 having the least (357×103 cell/ mm3). There was a significant (p<0.05) difference in the indices of biochemical activities between the extract-treated infected groups and the standard drug-treated group. Conclusion: This study suggests that the methanol extract of the hemolymph of S. argyrostoma larva exhibits trypanocidal activity, so it may be exploited as a suitable candidate for the development of trypanocidal drugs.

scholarly journals Differential virulence of camel Trypanosoma evansi isolates in mice

Parasitology ◽  
2018 ◽  
Vol 145 (9) ◽  
pp. 1235-1242 ◽  
Author(s):  
Christine M. Kamidi ◽  
Joanna Auma ◽  
Paul O. Mireji ◽  
Kariuki Ndungu ◽  
Rosemary Bateta ◽  
...  
Keyword(s):  
Body Weight ◽  
South America ◽  
Cell Volume ◽  
Packed Cell Volume ◽  
Post Infection ◽  
Trypanosoma Evansi ◽  
Type B ◽  
Mortality And Morbidity ◽  
Live Body Weight ◽  
High Virulence

AbstractThis study assessed the virulence of Trypanosoma evansi, the causative agent of camel trypanosomiasis (surra), affecting mainly camels among other hosts in Africa, Asia and South America, with high mortality and morbidity. Using Swiss white mice, we assessed virulence of 17 T. evansi isolates collected from surra endemic countries. We determined parasitaemia, live body weight, packed cell volume (PCV) and survivorship in mice, for a period of 60 days’ post infection. Based on survivorship, the 17 isolates were classified into three virulence categories; low (31–60 days), moderate (11–30 days) and high (0–10 days). Differences in survivorship, PCV and bodyweights between categories were significant and correlated (P < 0.05). Of the 10 Kenyan isolates, four were of low, five moderate and one (Type B) of high virulence. These findings suggest differential virulence between T. evansi isolates. In conclusion, these results show that the virulence of T. evansi may be region specific, the phenotype of the circulating parasite should be considered in the management of surra. There is also need to collect more isolates from other surra endemic regions to confirm this observation.

Solving the challenge of the blood–brain barrier to treat infections caused by Trypanosoma evansi: evaluation of nerolidol-loaded nanospheres in mice

Parasitology ◽  
2017 ◽  
Vol 144 (11) ◽  
pp. 1543-1550 ◽  
Author(s):  
MATHEUS D. BALDISSERA ◽  
CARINE F. SOUZA ◽  
ALINE A. BOLIGON ◽  
THIRSSA H. GRANDO ◽  
MARIÂNGELA F. DE SÁ ◽  
...  
Keyword(s):  
Brain Tissue ◽  
Blood Brain Barrier ◽  
High Performance ◽  
Drug Efficacy ◽  
Trypanosoma Evansi ◽  
Brain Barrier ◽  
Active Principle ◽  
Diminazene Aceturate ◽  
Blood Brain ◽  
The Brain

SUMMARYDespite significant advances in therapies against Trypanosoma evansi, its effective elimination from the central nervous system (CNS) remains a difficult task. The incapacity of trypanocidal drugs to cross the blood–brain barrier (BBB) after systemic administrations makes the brain the main refuge area for T. evansi. Nanotechnology is showing great potential to improve drug efficacy, such as nerolidol-loaded nanospheres (N-NS). Thus, the aim of this study was to investigate whether the treatment with N-NS was able to cross the BBB and to eliminate T. evansi from the CNS. High-performance liquid chromatography revealed that N-NS can cross the BBB of T. evansi-infected mice, while free nerolidol (F-N) neither the trypanocidal drug diminazene aceturate (D.A.) were not detected in the brain tissue. Polymerase chain reaction revealed that 100% of the animals treated with N-NS were negatives for T. evansi in the brain tissue, while all infected animals treated with F-N or D.A. were positives. Thus, we concluded that nanotechnology improves the therapeutic efficacy of nerolidol, and enables the transport of its active principle through the BBB. In summary, N-NS treatment can eliminate the parasite from the CNS, and possesses potential to treat infected animals.

scholarly journals Differential virulence of Trypanosoma brucei rhodesiense isolates does not influence the outcome of treatment with anti-trypanosomal drugs in the mouse model

2020 ◽  
Author(s):  
Kariuki Ndung’u ◽  
Grace Adira Murilla ◽  
John Kibuthu Thuita ◽  
Geoffrey Njuguna Ngae ◽  
Joanna Eseri Auma ◽  
...  
Keyword(s):  
Trypanosoma Brucei ◽  
Post Infection ◽  
Drug Resistant ◽  
Weight Changes ◽  
Trypanosoma Brucei Rhodesiense ◽  
Diminazene Aceturate ◽  
Reference Drug ◽  
Western Kenya ◽  
Biotechnology Research ◽  
Cure Rates

AbstractWe assessed the virulence and anti-trypanosomal drug sensitivity patterns of Trypanosoma brucei rhodesiense (Tbr) isolates in the Kenya Agricultural and Livestock Research Organization-Biotechnology Research Institute (KALRO-BioRI) cryobank. Specifically, the study focused on Tbr clones originally isolated from the western Kenya/eastern Uganda focus of human African Trypanosomiasis (HAT). Twelve (12) Tbr clones were assessed for virulence using groups(n=10) of Swiss White Mice monitored for 60 days post infection (dpi). Based on survival time, four classes of virulence were identified: (a) very-acute: 0-15, (b) acute: 16-30, (c) sub-acute: 31-45 and (d) chronic: 46-60 dpi. Other virulence biomarkers identified included: prepatent period (pp), parasitaemia progression, packed cell volume (PCV) and body weight changes. The test Tbr clones together with KALRO-BioRi reference drug-resistant and drug sensitive isolates were then tested for sensitivity to melarsoprol (mel B) pentamidine, diminazene aceturate and suramin, using mice groups (n= 5) treated with single doses of each drug at 24 hours post infection. Our results showed that the clones were distributed among four classes of virulence as follows: 3/12 (very-acute), 3/12 (acute), 2/12 (sub-acute) and 4/12 (chronic) isolates. Differences in survivorship, parasitaemia progression and PCV were significant (P<0.001) and correlated. The isolate considered to be drug resistant at KALRO-BioRI, KETRI 2538, was confirmed to be resistant to melarsoprol, pentamidine and diminazene aceturate but it was not resistant to suramin. At least 80% cure rates of all the test isolates was achieved with melarsoprol (1mg/Kg and 20 mg/kg), pentamidine (5 and 20 mg/kg), diminazene aceturate (5 mg/kg) and suramin (5 mg/kg) indicating that the isolates were not resistant to any of the drugs despite the differences in virulence. This study provides evidence of variations in virulence of Tbr isolates from a single HAT focus and confirms that these variations are not a significant determinant of isolate sensitivity to anti-trypanosomal drugs.

scholarly journals Evaluasi Pemberian Obat Diminazene Aceturate Secara In Vivo Pada Mencit (Mus musculus) yang Diinfeksi Isolat Trypanosoma evansi

2021 ◽  
Vol 39 (2) ◽  
pp. 185
Author(s):  
Reza Yesica ◽  
Bambang Sutrisno ◽  
Wisnu Nurcahyo
Keyword(s):  
Drug Resistance ◽  
Test Dose ◽  
Trypanosoma Evansi ◽  
Buffy Coat ◽  
Diminazene Aceturate ◽  
In Vivo Test ◽  
Negative Results ◽  
Central Java ◽  
And Control

Abstract Surra's disease is caused by Trypanosoma evansi parasite has been established as one of the strategic infectious animal diseases. Drug resistance in this case is one of the major challenges in handle and control them. The aim of this study is to evaluate the provision drug resistance diminazene aceturate (Tryponil®) on Trypanosoma evansi isolate from Pemalang and Brebes Central Java province with in vivo test in mice. Total 50 mice, BALB / c strain, male, 2 months, body weight ± 30 gram are obtained from LPPT-UGM, adapted for one week. Mice were divided into 10 groups consist of 5 each. Each mouse was infected with Trypanosoma evansi by intraperitonial route. Treatment was given when mice had reached the level of parasitemia 108 – 109 trypanosoma / mL of blood this was predicted 24 hours post-infection (Eisler et al., 2001). The administration of the drug tryapanosidal was done intraperitonial with doses 1mg/kg, 3mg / kg, 5 mg / kg and 7mg / kg. Observation of parasitemia did every 2 times in one week till 60 days of observation. Parasitemia observation was performed using 3 techniques. The first method was native examination used a microscope, if the negative results would be followed by MHCT (Microhaematocrit centrifugation Technique) and BCT (Buffy Coat Technique) according to OIE (2012). Data obtained from the treatment group were the level of parasitemia, the number of deaths and the number of live mice from each test dose. The results are analysed by standard logit or probit. The results of this study showed the effects of the drug Dimianzene aceturate on both isolates varied. On Brebes Isolate was effective at doses of 7 mg / kg BW (100%) and 5mg / kg BW (80%), whereas in the effective dose Pemalang isolate at 3 mg dose / kg BW (80%), 5 and 7 mg / kg BW (100%). While at the lowest dose of 1 mg / kg obtained a level of effectiveness of 0% in both isolates. It could be concluded that both isolates have different pathogens and indicate resistance subpopulation to diminazene aceturate.Keywords : diminazene aceturate, in vivo, resistance, Trypanosoma evansi. 

Combination of diminazene aceturate and resveratrol reduces the toxic effects of chemotherapy in treating Trypanosoma evansi infection

2015 ◽  
Vol 25 (1) ◽  
pp. 137-144 ◽  
Author(s):  
Matheus D. Baldissera ◽  
Nathieli B. Bottari ◽  
Virginia C. Rech ◽  
Vivian S. K. Nishihira ◽  
Camila B. Oliveira ◽  
...  
Keyword(s):  
Trypanosoma Evansi ◽  
Toxic Effects ◽  
Diminazene Aceturate

scholarly journals Occurrence of multiple drug resistance in Trypanosoma brucei rhodesiense isolated from sleeping sickness patients

2007 ◽  
Vol 74 (1) ◽  
Author(s):  
N. Maina ◽  
J.M. Kagira
Keyword(s):  
Trypanosoma Brucei ◽  
Multiple Drug Resistance ◽  
Prepatent Period ◽  
Sleeping Sickness ◽  
Cross Resistance ◽  
Control Group ◽  
Multiple Drug ◽  
Trypanosoma Brucei Rhodesiense ◽  
Diminazene Aceturate ◽  
The Mean

The occurrence of cross-resistance among melarsoprol-resistant Trypanosoma brucei rhodesiense isolates was investigated in this study. The isolates, T. b. rhodesiense KETRI 237, 2538, 1992, 2709, 2694 and 3530, had been obtained from sleeping sickness patients in Kenya and Uganda between 1960 and 1985. Five groups consisting of six mice each were inoculated intraperitoneally with 105 parasites of each isolate, and 24 h later treated with either melarsoprol, homidium chloride, diminazene aceturate or isometamidium chloride. The control group comprised infected but untreated mice. The mice were monitored for cure for a period of 60 days post-treatment. The mean prepatent period in the control mice was 5 days while the mean survival period was 22 days. Five of the stabilates, KETRI 237, 2538, 2709, 2694, and 3530, were confirmed to be melarsoprol resistant. Cross-resistance was observed, with the majority of the isolates being resistant to homidium chloride (5/6) and diminazene aceturate (5/6), but all were sensitive to isometamidium chloride (6/6). However T. b. rhodesiense KETRI 1992, which was previously considered as melarsoprol resistant, was sensitive to all the drugs tested. In conclusion, our study has revealed the existence of cross-resistance among the melarsoprol resistant isolates which could only be cured by isometamidium.

Sign in / Sign up

Export Citation Format

Share Document